Market closedNon-fractional

Vanda Pharmaceuticals/VNDA

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS), Fanapt for the treatment of schizophrenia and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from HETLIOZ product sales.

Ticker

VNDA

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Washington, United States

Employees

203

VNDA Metrics

BasicAdvanced
$305M
Market cap
-
P/E ratio
-$0.09
EPS
0.71
Beta
-
Dividend rate
$305M
0.71
4.708
4.616
1.197
1.64
-2.43%
-0.91%
1.698
0.56
0.72
-2.62
-30.81%
-132.49%
-11.11%
-45.60%

What the Analysts think about VNDA

Analyst Ratings

Majority rating from 1 analysts.
Buy

VNDA Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-8.64% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$47M
4.87%
Net income
-$4.1M
70.83%
Profit margin
-8.64%
63.02%

VNDA Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 55.56%
QuarterlyAnnual
Q4 22
Q2 23
Q3 23
Q4 23
Q1 24
Actual
$0.12
$0.03
-
-$0.04
-
Expected
$0.08
-$0.13
-$0.04
-$0.09
$0.05
Surprise
50.00%
-123.08%
-
-55.56%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Vanda Pharmaceuticals stock?

Vanda Pharmaceuticals (VNDA) has a market cap of $305M as of July 06, 2024.

What is the P/E ratio for Vanda Pharmaceuticals stock?

The price to earnings (P/E) ratio for Vanda Pharmaceuticals (VNDA) stock is 0 as of July 06, 2024.

Does Vanda Pharmaceuticals stock pay dividends?

No, Vanda Pharmaceuticals (VNDA) stock does not pay dividends to its shareholders as of July 06, 2024.

When is the next Vanda Pharmaceuticals dividend payment date?

Vanda Pharmaceuticals (VNDA) stock does not pay dividends to its shareholders.

What is the beta indicator for Vanda Pharmaceuticals?

Vanda Pharmaceuticals (VNDA) has a beta rating of 0.71. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy or sell Vanda Pharmaceuticals stock

Buy or sell Vanda Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing